LSD Program

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed
MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved
Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed
MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved
MindMed Inks $50M Credit Facility Deal With K2 HealthVentures For An Additional Operational Year
MindMed's Q2 2023: One Of Biggest Players In The Space Sustains Faith In LSD's Multiple Path Ahead

LSD Program Recent News

MindMed Reports Full-Year 2022 Financial Results, Highlighting Anxiety & Autism Studies
Clinical-stage biopharma company Mind Medicine (MindMed), Inc. (NASDAQ: MNMD) shared its financial results for the full year ended Dec. 31, 2022. Numbers show solid stability:
Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic
The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc.
Ceruvia Lifesciences Begins Dosing Volunteers In Research On Non Hallucinogenic LSD Compound
Clinical-stage psychedelics biopharma company Ceruvia Lifesciences has dosed the first participant in its Phase 1 trial on NYPRG-101, aka BOL-148, an LSD non-hallucinogenic analog with a clinical and experimental administration history that dates back to the 1950s.
Where Are Psychedelics Headed In 2023? These Two Heavy Hitters Share Their Plans
It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year.